{"id":"https://openalex.org/W7204135124","doi":"https://doi.org/10.1080/14737167.2026.2715978","title":"From \u201ccluster imitation\u201d to \u201cfirst generic\u201d: the impact of market exclusivity incentives on Chinese generic drug manufacturers","display_name":"From \u201ccluster imitation\u201d to \u201cfirst generic\u201d: the impact of market exclusivity incentives on Chinese generic drug manufacturers","publication_year":2026,"publication_date":"2026-08-24","ids":{"openalex":"https://openalex.org/W7204135124","doi":"https://doi.org/10.1080/14737167.2026.2715978","pmid":"https://pubmed.ncbi.nlm.nih.gov/42634878"},"language":"en","primary_location":{"id":"doi:10.1080/14737167.2026.2715978","doi":"https://doi.org/10.1080/14737167.2026.2715978","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14737167.2026.2715978","pdf_url":null,"source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics &amp; Outcomes Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5148007576","display_name":"Zhixue Liu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhixue Liu","raw_affiliation_strings":["Trinomab Biotechnology Co., Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Trinomab Biotechnology Co., Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5147957724","display_name":"Xiaoqin Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaoqin Chen","raw_affiliation_strings":["Nanjing Fumeiruixin Technology Co., Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nanjing Fumeiruixin Technology Co., Ltd","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5148017052","display_name":"Zonghua Wang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zonghua Wang","raw_affiliation_strings":["Nanjing Fumeiruixin Technology Co. Ltd"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nanjing Fumeiruixin Technology Co. Ltd","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101774451","display_name":"Yongfa Chen","orcid":"https://orcid.org/0000-0002-2459-5163","observed_orcids":["https://orcid.org/0000-0002-2459-5163"]},"institutions":[{"id":"https://openalex.org/I161716053","display_name":"China Pharmaceutical University","ror":"https://ror.org/01sfm2718","country_code":"CN","type":"education","lineage":["https://openalex.org/I161716053"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Yongfa Chen","raw_affiliation_strings":["China Pharmaceutical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"China Pharmaceutical University","institution_ids":["https://openalex.org/I161716053"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5101774451"],"corresponding_institution_ids":["https://openalex.org/I161716053"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.68304552,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12851","display_name":"Firm Innovation and Growth","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10856","display_name":"Intellectual Property and Patents","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1405","display_name":"Management of Technology and Innovation"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/generic-drugs","display_name":"generic drugs","score":0.7089999914169312},{"id":"https://openalex.org/keywords/market-exclusivity","display_name":"market exclusivity","score":0.9290000200271606},{"id":"https://openalex.org/keywords/pharmaceutical-innovation","display_name":"pharmaceutical innovation","score":0.5329999923706055},{"id":"https://openalex.org/keywords/r-d-intensity","display_name":"R&D intensity","score":0.9700000286102295},{"id":"https://openalex.org/keywords/patent-applications","display_name":"patent applications","score":0.9620000123977661},{"id":"https://openalex.org/keywords/corporate-ownership","display_name":"corporate ownership","score":0.47200000286102295},{"id":"https://openalex.org/keywords/market-competition","display_name":"market competition","score":0.5270000100135803},{"id":"https://openalex.org/keywords/chinese-pharmaceutical-industry","display_name":"Chinese pharmaceutical industry","score":0.6549999713897705}],"concepts":[{"id":"https://openalex.org/C29122968","wikidata":"https://www.wikidata.org/wiki/Q1414816","display_name":"Incentive","level":2,"score":0.785099983215332},{"id":"https://openalex.org/C2776396487","wikidata":"https://www.wikidata.org/wiki/Q506319","display_name":"Generic drug","level":3,"score":0.7793999910354614},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.6715999841690063},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.6690000295639038},{"id":"https://openalex.org/C40700","wikidata":"https://www.wikidata.org/wiki/Q1411783","display_name":"Industrial organization","level":1,"score":0.6194999814033508},{"id":"https://openalex.org/C31266012","wikidata":"https://www.wikidata.org/wiki/Q6554340","display_name":"Linkage (software)","level":3,"score":0.586899995803833},{"id":"https://openalex.org/C6422946","wikidata":"https://www.wikidata.org/wiki/Q857354","display_name":"Panel data","level":2,"score":0.552299976348877},{"id":"https://openalex.org/C66882249","wikidata":"https://www.wikidata.org/wiki/Q169336","display_name":"Homogeneous","level":2,"score":0.4675000011920929},{"id":"https://openalex.org/C16051113","wikidata":"https://www.wikidata.org/wiki/Q828814","display_name":"Market share","level":2,"score":0.45910000801086426},{"id":"https://openalex.org/C162853370","wikidata":"https://www.wikidata.org/wiki/Q39809","display_name":"Marketing","level":1,"score":0.4415000081062317},{"id":"https://openalex.org/C26517878","wikidata":"https://www.wikidata.org/wiki/Q228039","display_name":"Key (lock)","level":2,"score":0.40689998865127563},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.40450000762939453},{"id":"https://openalex.org/C2993777677","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Drug industry","level":2,"score":0.35199999809265137},{"id":"https://openalex.org/C2778938233","wikidata":"https://www.wikidata.org/wiki/Q7180757","display_name":"Pharmaceutical manufacturing","level":2,"score":0.3109000027179718},{"id":"https://openalex.org/C34974158","wikidata":"https://www.wikidata.org/wiki/Q131257","display_name":"Intellectual property","level":2,"score":0.30630001425743103},{"id":"https://openalex.org/C2776943663","wikidata":"https://www.wikidata.org/wiki/Q165687","display_name":"Human capital","level":2,"score":0.30379998683929443},{"id":"https://openalex.org/C100001284","wikidata":"https://www.wikidata.org/wiki/Q2248246","display_name":"Public economics","level":1,"score":0.30320000648498535},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.30140000581741333},{"id":"https://openalex.org/C28719098","wikidata":"https://www.wikidata.org/wiki/Q44946","display_name":"Point (geometry)","level":2,"score":0.29260000586509705},{"id":"https://openalex.org/C83646750","wikidata":"https://www.wikidata.org/wiki/Q193893","display_name":"Capital (architecture)","level":2,"score":0.28700000047683716},{"id":"https://openalex.org/C58546491","wikidata":"https://www.wikidata.org/wiki/Q1150207","display_name":"Competitive advantage","level":2,"score":0.2809999883174896},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.2712000012397766},{"id":"https://openalex.org/C162118730","wikidata":"https://www.wikidata.org/wiki/Q1128453","display_name":"Actuarial science","level":1,"score":0.2669999897480011},{"id":"https://openalex.org/C2991943566","wikidata":"https://www.wikidata.org/wiki/Q209380","display_name":"Chinese market","level":3,"score":0.26269999146461487},{"id":"https://openalex.org/C2910862244","wikidata":"https://www.wikidata.org/wiki/Q7240896","display_name":"Drug prices","level":2,"score":0.26080000400543213},{"id":"https://openalex.org/C182306322","wikidata":"https://www.wikidata.org/wiki/Q1779371","display_name":"Order (exchange)","level":2,"score":0.2547999918460846},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.2513999938964844}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1080/14737167.2026.2715978","doi":"https://doi.org/10.1080/14737167.2026.2715978","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14737167.2026.2715978","pdf_url":null,"source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics &amp; Outcomes Research","raw_type":"journal-article"},{"id":"pmid:42634878","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42634878","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of pharmacoeconomics & outcomes research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.6773999929428101,"display_name":"Industry, innovation and infrastructure","id":"https://metadata.un.org/sdg/9"},{"score":0.504800021648407,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.6258377432823181,"display_name":"Industry, innovation and infrastructure","id":"https://metadata.un.org/sdg/9"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":16,"referenced_works":["https://openalex.org/W1509488853","https://openalex.org/W2011651138","https://openalex.org/W2028035502","https://openalex.org/W2063394675","https://openalex.org/W2096684396","https://openalex.org/W2139122730","https://openalex.org/W2146010143","https://openalex.org/W2150291618","https://openalex.org/W2551099687","https://openalex.org/W2749645282","https://openalex.org/W2807951826","https://openalex.org/W3126147167","https://openalex.org/W4387572766","https://openalex.org/W4404829724","https://openalex.org/W4409540559","https://openalex.org/W4412765543"],"related_works":[],"abstract_inverted_index":{"BACKGROUND:":[0],"China's":[1],"generic":[2,31,42,69,149],"drug":[3,19,70,150],"industry":[4,174],"has":[5],"long":[6],"suffered":[7],"from":[8,51],"'clustering'":[9],"and":[10,102,124,145,159],"homogeneous":[11],"competition,":[12],"constraining":[13],"structural":[14],"upgrading.":[15],"In":[16],"2021,":[17],"the":[18,82,111,119,154],"patent":[20,103],"linkage":[21],"system":[22],"introduced":[23],"a":[24,34,64],"12-month":[25],"market":[26,88,135],"exclusivity":[27,89,136],"period":[28,137,158],"for":[29],"first-to-market":[30],"drugs,":[32],"representing":[33],"key":[35],"institutional":[36],"change":[37],"aimed":[38],"at":[39],"incentivizing":[40],"high-quality":[41],"development.":[43],"RESEARCH":[44],"DESIGN":[45],"AND":[46],"METHODS:":[47],"Using":[48],"panel":[49],"data":[50],"1,248":[52],"firm-year":[53],"observations":[54],"of":[55],"A-share":[56],"listed":[57],"pharmaceutical":[58,76,161],"companies":[59],"(2015-2023),":[60],"this":[61],"study":[62],"employs":[63],"difference-in-differences":[65],"model":[66],"comparing":[67],"chemical":[68],"manufacturers":[71],"(treatment":[72],"group)":[73,79],"with":[74,141],"other":[75],"sub-sectors":[77,129],"(control":[78],"to":[80],"estimate":[81],"net":[83],"policy":[84,120],"effect.":[85,121],"RESULTS:":[86],"The":[87,134],"incentive":[90],"significantly":[91],"increased":[92,142],"R&D":[93,114],"intensity":[94],"(by":[95,105],"approximately":[96],"1.2%":[97],"points,":[98],"p":[99,107],"<":[100,108],"0.01)":[101],"applications":[104],"18.5%,":[106],"0.05)":[109],"in":[110,126],"treatment":[112],"group.":[113],"human":[115],"capital":[116],"positively":[117,139],"moderates":[118],"Non-state-owned":[122],"enterprises":[123],"firms":[125],"highly":[127],"competitive":[128],"exhibit":[130],"stronger":[131],"responsiveness.":[132],"CONCLUSIONS:":[133],"is":[138],"associated":[140],"innovation":[143],"inputs":[144],"outputs":[146],"among":[147],"Chinese":[148],"manufacturers.":[151],"However,":[152],"given":[153],"short":[155],"post-policy":[156],"observation":[157],"concurrent":[160],"reforms,":[162],"these":[163],"findings":[164],"should":[165],"be":[166],"interpreted":[167],"cautiously":[168],"regarding":[169],"broad":[170],"causal":[171],"claims":[172],"about":[173],"transformation.":[175]},"counts_by_year":[],"updated_date":"2026-09-23T05:00:35.095934","created_date":"2026-08-25T00:00:00"}